Treatment of Parasitic Worm Infections

Introduction to Therapeutic Options

The American Society of Tropical Medicine and Hygiene recommends albendazole as the primary treatment for intestinal nematodes, including hookworm, Ascaris, and Trichuris, due to its high efficacy and safety profile 1, 2
The World Health Organization suggests ivermectin as the first-line treatment for strongyloidiasis and filarial infections, such as loiasis and lymphatic filariasis, due to its high cure rates and tolerability 2, 3

Albendazole works by blocking microtubule systems in parasites, inhibiting glucose uptake and transport, leading to cell death, and is effective against a wide range of parasites, including intestinal nematodes and tissue cestodes 1
Ivermectin disrupts neuromuscular transmission in parasites, leading to their death, and is effective against filarial worms, Strongyloides, and certain intestinal nematodes 3, 2

For hookworm infections, albendazole is superior to ivermectin, with a 98% cure rate, and is the recommended treatment 1, 2
For strongyloidiasis, ivermectin is the preferred treatment, with an 83% cure rate, and is recommended as the first-line treatment 2
For filarial infections, ivermectin is preferred for microfilarial reduction, particularly when microfilarial load is <8,000 mf/mL, while albendazole is used when microfilarial load is >8,000 mf/mL or when ivermectin is contraindicated 3, 6

Albendazole can cause hepatotoxicity and leukopenia, especially with prolonged treatment, and requires monitoring of liver enzymes and blood counts 7
Ivermectin is generally well-tolerated but can cause severe adverse events, including encephalitis, in hypermicrofilaremic patients (>8,000 mf/mL) with loiasis or onchocerciasis 3, 6

The Infectious Diseases Society of America recommends identifying the parasite or most likely parasite based on exposure history and clinical presentation, and using a treatment algorithm to guide therapy 1
For empiric treatment, the combination of albendazole 400 mg plus ivermectin 200 μg/kg as a single dose provides broad-spectrum coverage and is recommended for travelers or migrants from endemic areas with eosinophilia or prolonged exposure 1, 2